ALZ_Blog_DTOP_BelowTitle

Alzheimer’s Drug ‘Within Five Years’

A new study taking place in the United Kingdom has given those who fear Alzheimer’s reason for hope. A new drug, solanezumab, made by pharmaceutical company Eli Lilly appears to have an effect on patients exhibiting early-stage Alzheimer’s. Previous trials with solanezumab had focused only on people with later-stage Alzhemier’s with no effect.

The new trial, however, will focus on earlier cases of Alzheimers. People will be given solanezumab as a monthly 400mg injection for 18 months.

Dr Eric Karran, director of research at Alzheimer’s Research UK, said “I think the pathway now is if solanezumab is shown to work in mild Alzheimer’s disease then the pathway would be to give it earlier and earlier and earlier…and you could have confidence you will see an effect.”

“I am full of hope that we are going to have a breakthrough in five years,” he said.

Read more about this development in the fight against Alzheimer’s disease.

Medianet ALZ
Lockerdome ALZ – Desktop
The Alzheimer's Site is a place where people can come together to support those whose lives have been affected by Alzheimer's disease. In addition to sharing stories of hope and love, shopping for the cause, and signing petitions, visitors can take just a moment each day to click on the purple button to help provide care for those living with Alzheimer's disease and research for a brighter future. Visit The Alzheimer's Site and click today - it's free!